Compass Biotechnologies Inc. Provides Additional Information on the Acquisition of EFSAudio

SALT LAKE CITY, UT / ACCESSWIRE / February 17, 2016 / Compass Biotechnologies Inc. (OTC PINK: COBI) COBI (Compass) Compass Biotechnologies Inc.

Compass Biotechnologies Inc., (OTC PINKSHEETS: COBI.PK): EFSAudio was able to successfully raise over $19,000 in a Kickfurther campaign, funding the purchase order for three of their popular amps: the Motion Sound KP-500S, Motion Sound Pro 3X and the Motion Sound Pro 145: http://kickfurther.com/offer/help-motion-sound-get-in-motion.

Once the acquisition is completed, Compass intends to pay out the remaining EFSAudio Kickfurther payback balance ahead of schedule. Compass and EFSAudio will launch a follow-up Kickfurther campaign to fund a considerable number of units in anticipation of sales growth, existing product back orders, and IP developmental costs for upcoming products.

This Kickfurther funding was set up to meet the demand for EFSAudio's largest distributors. All of the products chosen for this funding have had great traction over the past 3 years. The KP 500 and the Pro 3X will have a new makeover that will increase efficiency and reduce manufacturing time. The Pro 145 will get this same treatment in the next quarter. Considering the company's current production backlog, EFSAudio fully expects to sell this conservative amount of product.

"We intend to be different from other OTC companies seeking operational capital, by building and funding the company with limited shareholder dilution," says CEO Rick Shykora. "The Kickfurther funding model provides a platform for the company to attract non-toxic financing for inventory costs and intellectual property development costs without causing dilution to the company's capital structure. Through this platform, we will be able to increase the company's inventory and sales capacity, which will dramatically reduce the need for outside funding for future production costs."

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact Person:

Rick Shykora
At: compassbiotechnologies@gmail.com
(972) 535-8931

SOURCE: Compass Biotechnologies Inc.